GoPro Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 103.8× GoPro Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while GoPro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| GPRO | RPRX | |
|---|---|---|
Market Cap | $243.50M | $25.27B |
Volume | 11,527,160 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $2.35 | $63.96 |
52-Week Low | $0.58 | $35.44 |
Typical Hold Time | 45 Days | 1 Days |
Enterprise Value | $302.28M | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 3.28% today, amid volatile trading following a recent merger announcement with Starman Optical. The company faces fundamental challenges with negative net income margins (-28.52%) and declining revenue, though valuation ratios appear low with P/E of 4.56 and P/S of 0.34. Technical indicators show a bullish overall signal with RSI at oversold levels, while analyst sentiment remains mixed with only 21% recommending Buy.
The proposed $285 million merger offers potential upside from current levels, but significant execution risks and ongoing cash burn (-$53M net cash flow) create substantial uncertainty. Investors face binary outcomes between merger completion benefits and continued operational struggles in a competitive camera market.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →